Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Price:
0.1601 USD
0.69%
Market Closed
Updated:
Apr 30, 2024
Sonoma Pharmaceuticals Inc
Cost of Revenue
|
Sonoma Pharmaceuticals Inc
Cost of Revenue Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Cost of Revenue
-$7.5m
|
CAGR 3-Years
15%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-4%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cost of Revenue
-$24.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cost of Revenue
-$10.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cost of Revenue
-$17.8B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cost of Revenue
-$15.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cost of Revenue
-$7.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-4%
|
See Also
What is Sonoma Pharmaceuticals Inc's Cost of Revenue?
Cost of Revenue
-7.5m
USD
-7.5m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Cost of Revenue amounts to -7.5m USD.
What is Sonoma Pharmaceuticals Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-4%
-4%
Over the last year, the Cost of Revenue growth was 13%. The average annual Cost of Revenue growth rates for Sonoma Pharmaceuticals Inc have been 15% over the past three years , 5% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet
